Giada Rotunno

Giada Rotunno

UNVERIFIED PROFILE

Are you Giada Rotunno?   Register this Author

Register author
Giada Rotunno

Giada Rotunno

Publications by authors named "Giada Rotunno"

Are you Giada Rotunno?   Register this Author

32Publications

870Reads

11Profile Views

Myelodysplasia as assessed by multiparameter flow cytometry refines prognostic stratification provided by genotypic risk in systemic mastocytosis.

Am J Hematol 2019 Aug 21;94(8):845-852. Epub 2019 May 21.

CRIMM, Centro di Ricerca e Innovazione per le Malattie Mieloproliferative, Azienda Ospedaliera Universitaria Careggi, Dipartimento di Medicina Sperimentale e Clinica, Denothe Excellence Center, Università degli Studi, Firenze, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25506DOI Listing
August 2019

Spectrum of mutations in primary myelofibrosis: prognostic impact of the p.G646Wfs*12 mutation.

Blood 2019 Jun 10;133(26):2802-2808. Epub 2019 May 10.

Centro di Ricerca e Innovazione per le Malattie Mieloproliferative (CRIMM), Dipartimento di Medicina Sperimentale e Clinica, Azienda Ospedaliera Universitaria Careggi, and.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood.2018879536DOI Listing
June 2019

Validation of the Mayo alliance prognostic system for mastocytosis.

Blood Cancer J 2019 02 11;9(2):18. Epub 2019 Feb 11.

CRIMM, Centro di Ricerca e Innovazione per le Malattie Mieloproliferative, Azienda Ospedaliera Universitaria Careggi, Dipartimento di Medicina Sperimentale e Clinica, Università degli Studi, Firenze, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-019-0179-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6370807PMC
February 2019

Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea.

Blood Cancer J 2018 11 22;8(12):122. Epub 2018 Nov 22.

CRIMM, Centro di Ricerca e Innovazione per le Malattie Mieloproliferative, Azienda Ospedaliera Universitaria Careggi, Dipartimento di Medicina Sperimentale e Clinica, Università degli Studi, Firenze, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-018-0152-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6250726PMC
November 2018

Clonal architecture of JAK2V617F mutated cells during treatment with ruxolitinib.

Hematol Oncol 2018 Feb 5;36(1):357-359. Epub 2017 May 5.

CRIMM-Center for Research and Innovation of Myeloproliferative Neoplasms, AOU Careggi, Department of Experimental and Clinical medicine, University of Florence, Florence, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hon.2424DOI Listing
February 2018

MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis.

J Clin Oncol 2018 02 9;36(4):310-318. Epub 2017 Dec 9.

Paola Guglielmelli, Giada Rotunno, Carmela Mannarelli, Annalisa Pacilli, Francesco Mannelli, and Alessandro M. Vannucchi, University of Florence, Azienda Ospedaliero Universitaria Careggi, Florence; Elisa Rumi, Vittorio Rosti, Giovanni Barosi, and Mario Cazzola, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo; Elisa Rumi and Mario Cazzola, University of Pavia, Pavia; Alessandro Rambaldi, University of Milan, Milan; Alessandro Rambaldi and Tiziano Barbui, Azienda Socio sanitaria Territoriale Papa Giovanni XXIII, Bergamo; Francesco Passamonti, University of Insubria, Varese, Italy; and Terra L. Lasho, Mythri Mudireddy, Maura Nicolosi, Animesh Pardanani, Curtis A. Hanson, Rhett P. Ketterling, Naseema Gangat, and Ayalew Tefferi, Mayo Clinic, Rochester, MN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.76.4886DOI Listing
February 2018

Targeted deep sequencing in polycythemia vera and essential thrombocythemia.

Blood Adv 2016 Nov 22;1(1):21-30. Epub 2016 Nov 22.

Centro Ricerca e Innovazione Malattie Mieloproliferative, Azienda Ospedaliera Universitaria Careggi, and Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy; and.

View Article

Download full-text PDF

Source
http://www.bloodadvances.org/lookup/doi/10.1182/bloodadvance
Publisher Site
http://dx.doi.org/10.1182/bloodadvances.2016000216DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5744051PMC
November 2016

Germline transmission of LNKE208Q variant in a family with myeloproliferative neoplasms.

Am J Hematol 2016 09 4;91(9):E356. Epub 2016 Jul 4.

CRIMM, Centro Di Ricerca E Innovazione per Le Malattie Mieloproliferative, Azienda Ospedaliera Universitaria Careggi, Dipartimento di Medicina Sperimentale e Clinica, Università Degli Studi, Firenze, DENOTHE Excellence Center, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.24437DOI Listing
September 2016

Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients.

Am J Hematol 2016 09 4;91(9):918-22. Epub 2016 Jul 4.

Department of Experimental and Clinical Medicine and DENOTHE Excellence Center, CRIMM-Center for Research and Innovation of Myeloproliferative Neoplasms, AOU Careggi, University of Florence, Florence, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.24442DOI Listing
September 2016

Ruxolitinib is an effective treatment for CALR-positive patients with myelofibrosis.

Br J Haematol 2016 06 25;173(6):938-40. Epub 2015 Aug 25.

Laboratorio Congiunto per le Malattie Mieloproliferative, Università degli Studi di Firenze, Azienda Ospedaliera Universitaria Careggi, Florence, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.13644DOI Listing
June 2016

What Do Molecular Tests Add to Prognostic Stratification in MF: Is It Time to Add These to Our Clinical Practice?

Curr Hematol Malig Rep 2015 Dec;10(4):380-7

CRIMM-Centro Ricerca e Innovazione delle Malattie Mieloproliferative croniche, Azienda Ospedaliera Universitaria Careggi, Palazzina 27/B, Cubo 3 Largo Brambilla 3, 50134, Florence, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11899-015-0285-yDOI Listing
December 2015

Feasibility of a workflow for the molecular characterization of single cells by next generation sequencing.

Biomol Detect Quantif 2015 Sep 12;5:23-9. Epub 2015 Sep 12.

Department of Clinical, Experimental and Biomedical Sciences, University of Florence, Florence, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bdq.2015.07.002DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4822219PMC
September 2015

JAK2V617F complete molecular remission in polycythemia vera/essential thrombocythemia patients treated with ruxolitinib.

Blood 2015 May;125(21):3352-3

Laboratorio Congiunto Malattie Mieloproliferative Croniche, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy Hematology Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy.

View Article

Download full-text PDF

Source
http://www.bloodjournal.org/cgi/doi/10.1182/blood-2015-01-62
Publisher Site
http://dx.doi.org/10.1182/blood-2015-01-624536DOI Listing
May 2015

Calreticulin: a new horizon for the testing and treatment of myeloproliferative neoplasms.

Expert Rev Hematol 2014 Aug 22;7(4):423-5. Epub 2014 May 22.

Laboratorio Congiunto MMPC, Department of Experimental and Clinical Medicine, University of Florence, Azienda Ospedaliera Universitaria Careggi, Florence, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/17474086.2014.920250DOI Listing
August 2014

Mutational analysis of BCORL1 in the leukemic transformation of chronic myeloproliferative neoplasms.

Ann Hematol 2014 Mar 21;93(3):523-4. Epub 2013 Jun 21.

Dipartimento di Medicina Sperimentale e Clinica, University of Florence, Largo Brambilla 3, 50134, Florence, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-013-1827-9DOI Listing
March 2014

Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia.

Blood 2014 Mar 26;123(10):1552-5. Epub 2013 Dec 26.

Department of Experimental and Clinical Medicine, University of Florence; and Azienda Ospedaliera-Universitaria Careggi, Florence, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2013-11-538983DOI Listing
March 2014

Co-targeting the PI3K/mTOR and JAK2 signalling pathways produces synergistic activity against myeloproliferative neoplasms.

J Cell Mol Med 2013 Nov 17;17(11):1385-96. Epub 2013 Nov 17.

Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jcmm.12162DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4117551PMC
November 2013